LOW-VOLUME · HOSP-MID
dalbavancin Side Effects
dalbavancin (also sold as Dalvance) is a LOW-VOLUME FAERS extract #491 of 524 by FAERS report count. Still opens on HOSP-MID: 22.7% mention hospitalization (207 reports).
Data updated 2026-05-15
- 911
- FAERS reports
Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.
dalbavancin: 22.7% mention hospitalization (207 reports). Death stamp DEATH-MARKED; volume band LOW-VOLUME #491 of 524 by FAERS report count.
Thinner FAERS extract for dalbavancin (Dalvance) (911 reports #491 of 524 by FAERS report count). 22.7% mention hospitalization (207 reports). Sparse books still carry named reaction rows when present; not medical advice.
Counts from the openFDA FAERS extract (2014–2025). Stamps SIGNAL · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
RASH leads 93 of 911 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (164 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 20 reports (2.2% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 14 |
| TREATMENT FAILURE | 3 |
| PYREXIA | 2 |
| CEREBROVASCULAR ACCIDENT | 1 |
| CHILLS | 1 |
| DRUG DOSE OMISSION | 1 |
| EMBOLISM | 1 |
| HAEMORRHAGE | 1 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 1 |
| NAUSEA | 1 |
| PERIPHERAL SWELLING | 1 |
| RASH | 1 |
| SEPSIS | 1 |
| SUDDEN DEATH | 1 |
Reactions in Hospitalization Reports
Hospitalization mid-share (207, 22.7%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| DYSPNOEA | 18 |
| PYREXIA | 15 |
| NAUSEA | 14 |
| HYPERSENSITIVITY | 13 |
| ACUTE KIDNEY INJURY | 12 |
| RASH | 12 |
| ANAPHYLACTIC REACTION | 11 |
| INFUSION RELATED REACTION | 11 |
| VOMITING | 11 |
| PAIN | 9 |
| PRURITUS | 9 |
| ERYTHEMA | 8 |
| CELLULITIS | 7 |
| CHILLS | 7 |
| HYPOTENSION | 7 |
| MUSCLE SPASMS | 7 |
| PERIPHERAL SWELLING | 7 |
| SEPSIS | 7 |
How to read dalbavancin FAERS figures (SIGNAL · DEATH-MARKED · HOSP-MID)
FAERS holds 911 voluntary reports linked to dalbavancin (Dalvance), 2014-2025. Death is listed on 20 (2.2%). Hospitalization appears on 207 (22.7%). Top co-reported indication: Product Used For Unknown Indication.
Sparse extract - named reactions and SEX-BALANCED skew still differ by drug; not a complete safety profile.
Read with dalbavancin
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.
ABS(total_reports) peer at 905 FAERS cases (Δ 6 lighter vs dalbavancin); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's SIGNAL · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 923 FAERS cases (Δ 12 heavier vs dalbavancin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 896 FAERS cases (Δ 15 lighter vs dalbavancin); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's SIGNAL · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 952 FAERS cases (Δ 41 heavier vs dalbavancin); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's SIGNAL · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 59.9 pp vs dalbavancin's DEATH-MARKED): CASELOAD · HOSP-MID.
dalbavancin stamps SIGNAL · SEX-BALANCED; class peers and methodology beat restating the same FAERS caveats on every effects URL.